Related Experiment Videos
Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy
1ICRF Molecular Oncology Laboratory, John Radcliffe Hospital, Oxford, UK.
Abstract:
Tumor angiogenesis is critical for the growth of primary cancers above 1-2 mm in diameter. A major vascular growth factor is VEGF, and approaches to inhibit VEGF have shown encouraging results in pre-clinical studies. The mechanisms involved in switching on angiogenesis involve activation of oncogenes and upregulation of the hypoxia-sensing pathway. These provide novel targets for therapy. Many anti-angiogenic drugs are in clinical trial currently and there are problems in assessing these types of drugs if they only cause disease stabilisation. It will be important to develop methods to assess inhibition of vascular growth in vivo. New generations of anti-angiogenesis drugs such as endostatin of angiostatin, which are more potent, may cause tumor regression, but this has not yet been studied in patients. These approaches for advanced disease should be more successful when applied early in an adjuvant situation. This will also require careful monitoring of long-term toxicity.
Insights
Targeting tumor angiogenesis, crucial for cancer growth, involves inhibiting vascular endothelial growth factor (VEGF). New anti-angiogenesis drugs show promise, but assessing their efficacy and long-term effects requires further study.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumor angiogenesis, the formation of new blood vessels, is essential for primary cancers to grow beyond 1-2 mm.
- Vascular Endothelial Growth Factor (VEGF) is a key driver of tumor angiogenesis.
- Activation of oncogenes and the hypoxia-sensing pathway are critical mechanisms initiating angiogenesis.
Purpose of the Study:
- To review the role of tumor angiogenesis in cancer progression.
- To discuss current and emerging anti-angiogenic therapies targeting VEGF and other pathways.
- To highlight challenges in assessing the efficacy of anti-angiogenic drugs and suggest future research directions.
Main Methods:
- Review of pre-clinical and clinical studies on anti-angiogenic therapies.
- Analysis of mechanisms underlying tumor angiogenesis.
- Discussion of challenges in evaluating drug efficacy, particularly for disease stabilization.
Main Results:
- Inhibiting VEGF has shown promise in pre-clinical studies for controlling tumor growth.
- Novel anti-angiogenesis drugs, including endostatin and angiostatin, are under clinical investigation.
- Assessing the efficacy of drugs causing disease stabilization presents a significant challenge.
Conclusions:
- Targeting tumor angiogenesis offers a promising therapeutic strategy for various cancers.
- Developing robust methods for assessing anti-angiogenic effects in vivo is crucial.
- Early application of potent anti-angiogenic agents, alongside careful toxicity monitoring, may improve outcomes in advanced disease and adjuvant settings.